

LIBRETTO-432

Selpercatinib in Early-Stage RET Fusion– Positive Non–Small-Cell Lung Cancer

Wu YL, Hochmair M, Yang Y, et al. N Engl J Med. 2026. doi:10.1056/NEJMoa2602628




ANNENBERG CENTER FOR HEALTH SCIENCES


AT EISENHOWER

Imparting knowledge. Improving patient care.

LIBRETTO-432: Selpercatinib Efficacy (Primary Analysis – Stage II or IIIA Disease)



LIBRETTO-432: Selpercatinib Efficacy (Overall Population)



LIBRETTO-432: Selpercatinib Safety*

All-Grade Adverse Events (Grade ≥ 3)	Selpercatinib (n=75)	Placebo (n=76)
ALT increased	63% (17%)	18% (1%)
AST increased	60% (19%)	16% (3%)
Diarrhea	39% (4%)	17% (0%)
Dry Mouth	40% (0%)	16% (0%)
Cough	27% (0%)	24% (0%)
Bilirubin increased	27% (1%)	14% (0%)
Hypertension	31% (11%)	11% (3%)
Constipation	23% (0%)	13% (0%)
Grade ≥ 3 adverse events	67%	24%
Discontinuations due to TRAEs	17%	1%

*Overall population

AST, aspartate aminotransferase; ALT, alanine transaminase; TRAE, treatment-related adverse events



ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER
Imparting knowledge. Improving patient care.

© Copyright 2025 Annenberg Center for Health Sciences | All Rights Reserved

Wu YL, et al. *N Engl J Med.* 2026.